| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.AJPATH.2010.08.004 |
| P8608 | Fatcat ID | release_ih5l3tw42bfgjegowgswvwrgeu |
| P932 | PMC publication ID | 3069922 |
| P698 | PubMed publication ID | 21224037 |
| P5875 | ResearchGate publication ID | 49744879 |
| P50 | author | Edwin De Pauw | Q30351787 |
| P2093 | author name string | Vincent Castronovo | |
| Andrei Turtoi | |||
| P2860 | cites work | Mass spectrometry-based proteomics | Q28182890 |
| Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry | Q28204943 | ||
| Laser capture microdissection | Q28293867 | ||
| Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo | Q28580251 | ||
| Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations | Q30751781 | ||
| Analysis and validation of proteomic data generated by tandem mass spectrometry | Q31131394 | ||
| Peptide sequence analysis | Q33231175 | ||
| Protein Equalizer Technology : the quest for a "democratic proteome". | Q33247929 | ||
| Ion formation mechanisms in UV-MALDI. | Q33260677 | ||
| Rational selection of the optimum MALDI matrix for top-down proteomics by in-source decay | Q33302850 | ||
| Identification of accessible human cancer biomarkers using ex vivo chemical proteomic strategies | Q33309341 | ||
| Ibritumomab tiuxetan for non-Hodgkin's lymphoma | Q33371489 | ||
| Quantitative proteomic analysis of single pancreatic islets | Q33511709 | ||
| Solid-phase extraction of N-linked glycopeptides | Q34271181 | ||
| Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry | Q34603412 | ||
| Detection technologies in proteome analysis | Q34642319 | ||
| Membrane proteins and membrane proteomics | Q34657071 | ||
| Electrospray: from ions in solution to ions in the gas phase, what we know now. | Q34988664 | ||
| Fibronectin as target for tumor therapy | Q36354769 | ||
| Ligand-based vascular targeting of disease | Q36677212 | ||
| Iodine 131 tositumomab in the treatment of non-Hodgkin's lymphoma | Q36839758 | ||
| Cell membrane proteomic analysis identifies proteins differentially expressed in osteotropic human breast cancer cells | Q36840298 | ||
| Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin | Q37199950 | ||
| A human proteome detection and quantitation project | Q37210681 | ||
| Application of electron transfer dissociation (ETD) for the analysis of posttranslational modifications | Q37313192 | ||
| Cell surface and secreted protein profiles of human thyroid cancer cell lines reveal distinct glycoprotein patterns | Q37326598 | ||
| Mass spectrometry (LC-MS/MS) site-mapping of N-glycosylated membrane proteins for breast cancer biomarkers. | Q37385278 | ||
| Sample preparation and fractionation for proteome analysis and cancer biomarker discovery by mass spectrometry | Q37394015 | ||
| Proteomics strategies for target identification and biomarker discovery in cancer. | Q37410428 | ||
| Targeted proteomic strategy for clinical biomarker discovery | Q37453847 | ||
| Strategies for analysis of the glycosylation of proteins: current status and future perspectives | Q37511909 | ||
| Imaging mass spectrometry: hype or hope? | Q38451237 | ||
| Identification of N-glycosylation sites on secreted proteins of human hepatocellular carcinoma cells with a complementary proteomics approach | Q39887058 | ||
| Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. | Q39980497 | ||
| Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature | Q40259543 | ||
| Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging | Q44944204 | ||
| Purification of biotinylated proteins on streptavidin resin: a protocol for quantitative elution | Q44993120 | ||
| Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients | Q46170695 | ||
| Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis | Q46362548 | ||
| In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature | Q46396196 | ||
| Paul Ehrlich's magic bullet concept: 100 years of progress | Q48322740 | ||
| Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. | Q48535535 | ||
| Selective targeted delivery of TNFalpha to tumor blood vessels. | Q53855595 | ||
| Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder. | Q54595989 | ||
| Preface | Q56942501 | ||
| Identification of the surface-accessible, lineage-specific vascular proteome by two-dimensional peptide mapping | Q57912046 | ||
| Identification of specific reachable molecular targets in human breast cancer using a versatileex vivo proteomic method | Q57912080 | ||
| A Chemical Proteomics Approach for the Identification of Accessible Antigens Expressed in Human Kidney Cancer | Q57912088 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 12-18 | |
| P577 | publication date | 2010-12-23 | |
| P1433 | published in | The American Journal of Pathology | Q4744259 |
| P1476 | title | Innovative proteomics for the discovery of systemically accessible cancer biomarkers suitable for imaging and targeted therapies | |
| P478 | volume | 178 |
| Q61800299 | Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies |
| Q37972138 | Infrared spectroscopy and microscopy in cancer research and diagnosis |
| Q44619320 | Investigation of parameters influencing incorporation, retention and cellular cytotoxicity in liposomal formulations of poorly soluble camptothecin |
| Q53192395 | [Asporin: the protective wall against triple-negative breast cancer]. |
Search more.